Kushvinder Kumar, Yoshikazu Honda-Okubo, Pradeep K Das, Anshuman Dixit, Kamal Nain Singh, David A Winkler, Nikolai Petrovsky, Deepak B Salunke
{"title":"Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 Modulators.","authors":"Kushvinder Kumar, Yoshikazu Honda-Okubo, Pradeep K Das, Anshuman Dixit, Kamal Nain Singh, David A Winkler, Nikolai Petrovsky, Deepak B Salunke","doi":"10.1002/cmdc.202501053","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple heterocyclic scaffolds have been found to exhibit agonist or antagonist activity at toll-like receptors (TLRs) with varying degrees of selectivity for the subtypes. TLR7 and 8 agonists are potentially valuable vaccine adjuvants while antagonists show useful activity against autoimmune diseases and cancer. A pyrazolo[1,5-c]quinazoline based compound 23, an unexplored scaffold in the domain of TLR7/8, was synthesized by analogy with lead agonists and antagonists from the literature. Compound 23 exhibited moderate agonist activity for both TLR7 and TLR8. The effect of structural modifications at the C1, C8, C9, and C10 position of the pyrazolo[1,5-c]quinazoline scaffold on hTLR7/8 activity was investigated by synthesizing a focused library of compounds. Although none of the compounds had agonist activity, three compounds were found to be dual TLR7/8 antagonists. These findings add to the existing structure-activity relationship knowledge of the tricyclic TLR7/8 modulators that will aid subsequent discovery and optimization of new drug candidates.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 8","pages":"e202501053"},"PeriodicalIF":3.4000,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202501053","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple heterocyclic scaffolds have been found to exhibit agonist or antagonist activity at toll-like receptors (TLRs) with varying degrees of selectivity for the subtypes. TLR7 and 8 agonists are potentially valuable vaccine adjuvants while antagonists show useful activity against autoimmune diseases and cancer. A pyrazolo[1,5-c]quinazoline based compound 23, an unexplored scaffold in the domain of TLR7/8, was synthesized by analogy with lead agonists and antagonists from the literature. Compound 23 exhibited moderate agonist activity for both TLR7 and TLR8. The effect of structural modifications at the C1, C8, C9, and C10 position of the pyrazolo[1,5-c]quinazoline scaffold on hTLR7/8 activity was investigated by synthesizing a focused library of compounds. Although none of the compounds had agonist activity, three compounds were found to be dual TLR7/8 antagonists. These findings add to the existing structure-activity relationship knowledge of the tricyclic TLR7/8 modulators that will aid subsequent discovery and optimization of new drug candidates.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.